AcelRx Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Dzuveo (under development in the U.S. as Dsuvia) for...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
AcelRx Pharmaceuticals announced today the approval of Dsuvia (sufentanil nanotab) by the FDA, indicated for the management of acute pain...
FDA Commissioner Scott Gottlieb, M.D.,statement on the agency�s approval of Dsuvia :"The crisis of opioid addiction is an issue of...